Revista espanola de cardiologia最新文献

英文中文

Propuesta de modelo asistencial para el implante urgente de marcapasos 紧急起搏器植入术的拟议护理模式

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-05-13 DOI: 10.1016/j.recesp.2024.04.020

引用次数: 0

Revisión sistemática y metanálisis de la mortalidad en la miocardiopatía chagásica crónica frente a otras miocardiopatías: ¿mayor riesgo o ficción? 慢性恰加斯病心肌病与其他心肌病死亡率的系统回顾和荟萃分析：风险增加还是子虚乌有？

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-05-11 DOI: 10.1016/j.recesp.2024.02.022

Introduction and objectives

Although multiple studies suggest that chronic Chagas cardiomyopathy (CCC) has higher mortality than other cardiomyopathies, the absence of meta-analyses supporting this perspective limits the possibility of generating robust conclusions. The aim of this study was to systematically evaluate the current evidence on mortality risk in CCC compared with that of other cardiomyopathies.

Methods

PubMed/Medline and EMBASE were searched for studies comparing mortality risk between patients with CCC and those with other cardiomyopathies, including in the latter nonischemic cardiomyopathy (NICM), ischemic cardiomyopathy, and non-Chagas cardiomyopathy (nonCC). A random-effects meta-analysis was performed to combine the effects of the evaluated studies.

Results

A total of 37 studies evaluating 17 949 patients were included. Patients with CCC had a significantly higher mortality risk compared with patients with NICM (HR, 2.04; 95%CI, 1.60-2.60; I², 47%; 8 studies) and non-CC (HR, 2.26; 95%CI, 1.65-3.10; I², 71%; 11 studies), while no significant association was observed compared with patients with ischemic cardiomyopathy (HR, 1.72; 95%CI, 0.80-3.66; I², 69%; 4 studies) in the adjusted-measures meta-analysis.

Conclusions

Patients with CCC have an almost 2-fold increased mortality risk compared with individuals with heart failure secondary to other etiologies. This finding highlights the need for effective public policies and targeted research initiatives to optimally address the challenges of CCC.

Full English text available from:www.revespcardiol.org/en

引言和目的虽然多项研究表明慢性恰加斯氏心肌病（CCC）的死亡率高于其他心肌病，但由于缺乏支持这一观点的荟萃分析，因此无法得出可靠的结论。本研究的目的是系统评估目前有关 CCC 与其他心肌病死亡率风险比较的证据。研究方法在 PubMed/Medline 和 EMBASE 上搜索了比较 CCC 患者与其他心肌病患者死亡率风险的研究，包括后者中的非缺血性心肌病 (NICM)、缺血性心肌病和非恰加斯心肌病 (nonCC)。结果共纳入了 37 项研究，对 17 949 名患者进行了评估。与 NICM 患者（HR，2.04；95%CI，1.60-2.60；I2，47%；8 项研究）和非 CCC 患者（HR，2.26；95%CI，1.65-3.10；I2，71%；11 项研究）相比，CCC 患者的死亡风险明显更高，而与缺血性心肌病患者（HR，1.结论与继发于其他病因的心力衰竭患者相比，CCC 患者的死亡风险几乎增加了 2 倍。这一发现突出表明，需要有效的公共政策和有针对性的研究措施，以最佳方式应对 CCC 带来的挑战。英文全文可从以下网站获取：www.revespcardiol.org/en。

{"title":"Revisión sistemática y metanálisis de la mortalidad en la miocardiopatía chagásica crónica frente a otras miocardiopatías: ¿mayor riesgo o ficción?","authors":"","doi":"10.1016/j.recesp.2024.02.022","DOIUrl":"10.1016/j.recesp.2024.02.022","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Although multiple studies suggest that chronic Chagas cardiomyopathy (<span>CCC</span>) has higher mortality than other cardiomyopathies, the absence of meta-analyses supporting this perspective limits the possibility of generating robust conclusions. The aim of this study was to systematically evaluate the current evidence on mortality risk in CCC compared with that of other cardiomyopathies.</div></div><div><h3>Methods</h3><div>PubMed/Medline and EMBASE were searched for studies comparing mortality risk between patients with CCC and those with other cardiomyopathies, including in the latter nonischemic cardiomyopathy (NICM), ischemic cardiomyopathy, and non-Chagas cardiomyopathy (nonCC). A random-effects meta-analysis was performed to combine the effects of the evaluated studies.</div></div><div><h3>Results</h3><div>A total of 37 studies evaluating 17 949 patients were included. Patients with CCC had a significantly higher mortality risk compared with patients with NICM (HR, 2.04; 95%CI, 1.60-2.60; I<sup>2</sup>, 47%; 8 studies) and non-CC (HR, 2.26; 95%CI, 1.65-3.10; I<sup>2</sup>, 71%; 11 studies), while no significant association was observed compared with patients with ischemic cardiomyopathy (HR, 1.72; 95%CI, 0.80-3.66; I<sup>2</sup>, 69%; 4 studies) in the adjusted-measures meta-analysis.</div></div><div><h3>Conclusions</h3><div>Patients with CCC have an almost 2-fold increased mortality risk compared with individuals with heart failure secondary to other etiologies. This finding highlights the need for effective public policies and targeted research initiatives to optimally address the challenges of CCC.</div><div><em>Full English text available from</em>:<span><span>www.revespcardiol.org/en</span><svg><path></path></svg></span></div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"77 10","pages":"Pages 843-850"},"PeriodicalIF":5.9,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141041657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Estado nutricional al ingreso y pronóstico en el shock cardiogénico 心源性休克患者入院时的营养状况和预后

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-05-10 DOI: 10.1016/j.recesp.2024.05.001

引用次数: 0

Pericarditis aguda por fiebre Q: una manifestación poco frecuente Q 热引起的急性心包炎：罕见病例

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-05-10 DOI: 10.1016/j.recesp.2024.05.003

Ana Belén Merón Pino, Andrea Alonso Campana, Eugenio Picazo Feu, Miguel Ángel Vallejo Ruiz, Alejandra Vaello Paños

引用次数: 0

Resultados de un servicio ininterrumpido de implante urgente de marcapasos permanente 全天候紧急永久起搏器植入服务的成果

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-05-09 DOI: 10.1016/j.recesp.2024.03.005

Introduction and objectives

Most of the complications associated with acute and symptomatic bradyarrhythmia (ASB) occur in the time from diagnosis to permanent pacemaker implantation (PPI). We aimed to evaluate the outcomes of an urgent 24/7 PPI service (PPI-24/7) for patients with ASB.

Methods

A total of 664 patients undergoing first-time PPI for ASB were prospectively assessed during 2 periods of identical length (18 months): 341 patients who underwent the procedure during working hours only (PPI-WH), and 323 patients who underwent the procedure after the implementation of the PPI-24/7 service. The primary safety endpoint was established as the cumulative 180-day incidence of complications related to the index arrhythmia and device implant. The primary efficacy endpoint was determined as the average number of hospital stays per patient.

Results

The PPI-24/7 period was associated with a significant shortening of the time from diagnosis to implantation (median [interquartile range]): 3 hours [2-6] vs 16 [5-21]). The cumulative incidence of patients with complications at 180 days was lower in the PPI-24/7 period: 9% vs 17% (adjusted odds ratio, 0.5; P = .002), due to a significant reduction in preimplant complications: 2.5% vs 12% (P < .001). The average number of hospital stays was reduced by 2 per patient in the PPI-24/7 period (nonparametric P < .001). PPI-24/7 implants performed outside working hours (n = 178) were safe, with a 180-day cumulative incidence in procedure-related complications of 3.9%.

Conclusions

Among patients with ASB, PPI-24/7 was associated with a significant reduction in patient morbidity and efficient hospital resource use.

导言和目的急性症状性心动过缓（ASB）的相关并发症大多发生在从诊断到永久起搏器植入（PPI）的过程中。我们的目的是评估为 ASB 患者提供的全天候紧急 PPI 服务（PPI-24/7）的效果。方法在两个相同时间段（18 个月）内对 664 名因 ASB 首次接受 PPI 的患者进行了前瞻性评估：在两个相同的时间段（18 个月）内，共对 664 名首次接受 PPI 治疗的 ASB 患者进行了前瞻性评估：341 名患者仅在工作时间接受治疗（PPI-WH），323 名患者在实施 PPI-24/7 服务后接受治疗。主要安全性终点确定为 180 天内与指数心律失常和设备植入相关的并发症累积发生率。PPI-24/7服务期显著缩短了从诊断到植入的时间（中位数[四分位间范围]：3小时[2-6小时]对16小时）：3小时 [2-6] vs 16 [5-21]）。在 PPI-24/7 期间，患者在 180 天内出现并发症的累计发生率较低：9% vs 17%（调整后的几率比，0.5；P = .002），这是因为植入前并发症显著减少：2.5%对12%（P = .001）。在 PPI-24/7 期间，每位患者的平均住院次数减少了 2 次（非参数 P < .001）。在工作时间以外进行的 PPI-24/7 植入手术（n = 178）是安全的，180 天内手术相关并发症的累积发生率为 3.9%。

{"title":"Resultados de un servicio ininterrumpido de implante urgente de marcapasos permanente","authors":"","doi":"10.1016/j.recesp.2024.03.005","DOIUrl":"10.1016/j.recesp.2024.03.005","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Most of the complications associated with acute and symptomatic bradyarrhythmia (ASB) occur in the time from diagnosis to permanent pacemaker implantation (PPI). We aimed to evaluate the outcomes of an urgent 24/7 PPI service (PPI-24/7) for patients with ASB.</div></div><div><h3>Methods</h3><div>A total of 664 patients undergoing first-time PPI for ASB were prospectively assessed during 2 periods of identical length (18 months): 341 patients who underwent the procedure during working hours only (PPI-WH), and 323 patients who underwent the procedure after the implementation of the PPI-24/7 service. The primary safety endpoint was established as the cumulative 180-day incidence of complications related to the index arrhythmia and device implant. The primary efficacy endpoint was determined as the average number of hospital stays per patient.</div></div><div><h3>Results</h3><div>The PPI-24/7 period was associated with a significant shortening of the time from diagnosis to implantation (median [interquartile range]): 3hours [2-6] vs 16 [5-21]). The cumulative incidence of patients with complications at 180 days was lower in the PPI-24/7 period: 9% vs 17% (adjusted odds ratio, 0.5; <em>P</em>      <!-->178) were safe, with a 180-day cumulative incidence in procedure-related complications of 3.9%.</div></div><div><h3>Conclusions</h3><div>Among patients with ASB, PPI-24/7 was associated with a significant reduction in patient morbidity and efficient hospital resource use.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"77 11","pages":"Pages 899-909"},"PeriodicalIF":5.9,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141025142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Desafíos en el avance de la sonda de ecocardiografía transesofágica: identificación de causas y soluciones 推进经食道超声心动图探头的挑战：找出原因和解决方案

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-05-08 DOI: 10.1016/j.recesp.2024.04.016

引用次数: 0

Valvulitis: un nuevo criterio ecocardiográfico para el diagnóstico de endocarditis infecciosa de bioprótesis de válvula aórtica 瓣膜炎：诊断主动脉瓣生物假体感染性心内膜炎的新超声心动图标准

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-05-07 DOI: 10.1016/j.recesp.2024.03.001

Introduction and objectives

Diffuse homogeneous hypoechoic leaflet thickening, with a wavy leaflet motion documented by transesophageal echocardiography (TEE), has been described in some cases of prosthetic valve endocarditis (PVE) involving aortic bioprosthesis (AoBio-PVE). This echocardiographic finding has been termed valvulitis. We aimed to estimate the prevalence of valvulitis, precisely describe its echocardiographic characteristics, and determine their clinical significance in patients with AoBio-PVE.

Methods

From 2011 to 2022, 388 consecutive patients with infective endocarditis (IE) admitted to a tertiary care hospital were prospectively included in a multipurpose database. For this study, all patients with AoBio-PVE (n = 86) were selected, and their TEE images were thoroughly evaluated by 3 independent cardiologists to identify all cases of valvulitis.

Results

The prevalence of isolated valvulitis was 12.8%, and 20.9% of patients had valvulitis accompanied by other classic echocardiographic findings of IE. A total of 9 out of 11 patients with isolated valvulitis had significant valve stenosis, whereas significant aortic valve regurgitation was documented in only 1 patient. Compared with the other patients with AoBio-PVE, cardiac surgery was less frequently performed in patients with isolated valvulitis (27.3% vs 62.7%, P = .017). In 4 out of 5 patients with valve stenosis who did not undergo surgery but underwent follow-up TEE, valve gradients significantly improved with appropriate antibiotic therapy.

Conclusions

Valvulitis can be the only echocardiographic finding in infected AoBio and needs to be identified by imaging specialists for early diagnosis. However, this entity is a diagnostic challenge and additional imaging techniques might be required to confirm the diagnosis. Larger series are needed.

导言和目的经食道超声心动图（TEE）显示，一些涉及主动脉生物假体（AoBio-PVE）的人工瓣膜心内膜炎（PVE）病例出现弥漫性同质低回声瓣叶增厚，并伴有波浪形瓣叶运动。这种超声心动图检查结果被称为瓣膜炎。我们旨在估算瓣膜炎的患病率，精确描述其超声心动图特征，并确定其在 AoBio-PVE 患者中的临床意义。结果孤立性瓣膜炎的发病率为12.8%，20.9%的患者瓣膜炎伴有其他典型的IE超声心动图检查结果。在11名孤立性瓣膜炎患者中，共有9名患者有明显的瓣膜狭窄，而只有1名患者有明显的主动脉瓣反流。与其他患有 AoBio-PVE 的患者相比，孤立性瓣膜炎患者接受心脏手术的比例较低（27.3% 对 62.7%，P = .017）。结论瓣膜炎可能是感染性 AoBio 的唯一超声心动图检查结果，需要由影像学专家识别以进行早期诊断。然而，这种疾病在诊断上是一个挑战，可能需要额外的成像技术来确诊。需要更大规模的系列研究。

{"title":"Valvulitis: un nuevo criterio ecocardiográfico para el diagnóstico de endocarditis infecciosa de bioprótesis de válvula aórtica","authors":"","doi":"10.1016/j.recesp.2024.03.001","DOIUrl":"10.1016/j.recesp.2024.03.001","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Diffuse homogeneous hypoechoic leaflet thickening, with a wavy leaflet motion documented by transesophageal echocardiography (TEE), has been described in some cases of prosthetic valve endocarditis (PVE) involving aortic bioprosthesis (AoBio-PVE). This echocardiographic finding has been termed valvulitis. We aimed to estimate the prevalence of valvulitis, precisely describe its echocardiographic characteristics, and determine their clinical significance in patients with AoBio-PVE.</div></div><div><h3>Methods</h3><div>From 2011 to 2022, 388 consecutive patients with infective endocarditis (IE) admitted to a tertiary care hospital were prospectively included in a multipurpose database. For this study, all patients with AoBio-PVE (n=86) were selected, and their TEE images were thoroughly evaluated by 3 independent cardiologists to identify all cases of valvulitis.</div></div><div><h3>Results</h3><div>The prevalence of isolated valvulitis was 12.8%, and 20.9% of patients had valvulitis accompanied by other classic echocardiographic findings of IE. A total of 9 out of 11 patients with isolated valvulitis had significant valve stenosis, whereas significant aortic valve regurgitation was documented in only 1 patient. Compared with the other patients with AoBio-PVE, cardiac surgery was less frequently performed in patients with isolated valvulitis (27.3% vs 62.7%, <em>P <!-->.017). In 4 out of 5 patients with valve stenosis who did not undergo surgery but underwent follow-up TEE, valve gradients significantly improved with appropriate antibiotic therapy.</div></div><div><h3>Conclusions</h3><div>Valvulitis can be the only echocardiographic finding in infected AoBio and needs to be identified by imaging specialists for early diagnosis. However, this entity is a diagnostic challenge and additional imaging techniques might be required to confirm the diagnosis. Larger series are needed.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"77 10","pages":"Pages 859-867"},"PeriodicalIF":5.9,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141033702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hipertensión arterial pulmonar asociada a cortocircuitos pretricuspídeos: perfil de riesgo y supervivencia 与前三尖瓣分流相关的肺动脉高压：风险和存活概况

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-05-07 DOI: 10.1016/j.recesp.2024.04.014

引用次数: 0

Certificación de programas de cardio-onco-hematología: una oportunidad para mejorar la calidad asistencial de los pacientes con cáncer 心血肿瘤项目认证：提高癌症患者护理质量的契机

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-05-01 DOI: 10.1016/j.recesp.2024.04.013

引用次数: 0

Tomografía computarizada espectral en el abordaje del MINOCA MINOCA 方法中的光谱计算机断层扫描

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-05-01 DOI: 10.1016/j.recesp.2024.03.006

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Revista espanola de cardiologia

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀